Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
- PMID: 12177114
- DOI: 10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
Abstract
Purpose: To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural mesothelioma (MPM). The pharmacokinetics of both agents was investigated.
Patients and methods: Twenty-seven patients (23 male, four female) with MPM were treated on five escalating dose levels. Doses ranged from pemetrexed 400 mg/m(2) (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL.min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m(2), carboplatin AUC 6 mg/mL.min. All patients had a World Health Organization performance status of 1. A total of 163 courses of treatment were administered (median, six; range, one to 10).
Results: The main toxicity was hematologic, particularly neutropenia, although this was characteristically short-lived and caused few clinical problems. The MTD was pemetrexed 500 mg/m(2), carboplatin AUC 6, because three of the five patients treated at this dose level experienced a dose-limiting toxicity. Eight partial responses (in 25 assessable patients) were observed for a response rate of 32%. Seventy percent of patients noticed an improvement in symptoms, usually (84%) after only two courses. Median time to progression was 305 days, and median survival time was 451 days.
Conclusion: The MTD was pemetrexed 500 mg/m(2) and carboplatin AUC 6 mg/mL.min. The recommended phase II dose of the combination is pemetrexed 500 mg/m(2) and carboplatin AUC 5 mg/mL.min. The combination is both active and well tolerated in MPM and deserves further exploration.
Similar articles
-
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6. J Thorac Oncol. 2008. PMID: 18594322 Clinical Trial.
-
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.J Clin Oncol. 2006 Mar 20;24(9):1443-8. doi: 10.1200/JCO.2005.04.3190. J Clin Oncol. 2006. PMID: 16549838 Clinical Trial.
-
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.Clin Lung Cancer. 2010 Jan;11(1):30-5. doi: 10.3816/CLC.2010.n.005. Clin Lung Cancer. 2010. PMID: 20085865 Clinical Trial.
-
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.J Thorac Oncol. 2006 Jul;1(6):591-601. J Thorac Oncol. 2006. PMID: 17409924 Review.
-
Pemetrexed: a multitargeted antifolate.Clin Ther. 2005 Sep;27(9):1343-82. doi: 10.1016/j.clinthera.2005.09.010. Clin Ther. 2005. PMID: 16291410 Review.
Cited by
-
A nanoscale electrochemical guanine DNA-biosensor based on a flower-like nanocomposite of Tb-doped ZnO for the sensitive determination of pemetrexed.RSC Adv. 2023 Oct 9;13(42):29450-29462. doi: 10.1039/d3ra03983h. eCollection 2023 Oct 4. RSC Adv. 2023. PMID: 37818257 Free PMC article.
-
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.Front Oncol. 2022 Jun 17;12:916839. doi: 10.3389/fonc.2022.916839. eCollection 2022. Front Oncol. 2022. PMID: 35785199 Free PMC article. Review.
-
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease.Molecules. 2020 Sep 1;25(17):3987. doi: 10.3390/molecules25173987. Molecules. 2020. PMID: 32882995 Free PMC article. Review.
-
BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.PLoS One. 2018 Aug 29;13(8):e0203003. doi: 10.1371/journal.pone.0203003. eCollection 2018. PLoS One. 2018. PMID: 30157247 Free PMC article.
-
Anticancer Drug-Induced Acute Kidney Injury.Kidney Int Rep. 2017 Feb 16;2(4):504-514. doi: 10.1016/j.ekir.2017.02.008. eCollection 2017 Jul. Kidney Int Rep. 2017. PMID: 29318217 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical